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Abstract
Background: NICE guidelines state cognitive behavioural therapy (CBT) is a front-line psychological treatment for
people presenting with depression in primary care. Counselling for Depression (CfD), a form of Person-Centred
Experiential therapy, is also offered within Improving Access to Psychological Therapies (IAPT) services for moderate
depression but its effectiveness for severe depression has not been investigated. A full-scale randomised controlled
trial to determine the efficacy and cost-effectiveness of CfD is required.
Methods: PRaCTICED is a two-arm, parallel group, non-inferiority randomised controlled trial comparing CfD against CBT.
It is embedded within the local IAPT service using a stepped care service delivery model where CBT and CfD are routinely
offered at step 3. Trial inclusion criteria comprise patients aged 18 years or over, wishing to work on their depression,
judged to require a step 3 intervention, and meeting an ICD-10 diagnosis of moderate or severe depression. Patients are
randomised using a centralised, web-based system to CfD or CBT with each treatment being delivered up to a maximum
20 sessions. Both interventions are manualised with treatment fidelity tested via supervision and random sampling of
sessions using adherence/competency scales. The primary outcome measure is the Patient Health Questionnaire-9
collected at baseline, 6 and 12 months. Secondary outcome measures tap depression, generic psychological distress,
anxiety, functioning and quality of life. Cost-effectiveness is determined by a patient service receipt questionnaire. Exit
interviews are conducted with patients by research assessors blind to treatment allocation. The trial requires 500 patients
(250 per arm) to test the non-inferiority hypothesis of −2 PHQ-9 points at the one-sided, 2.5% significance level with 90%
power, assuming no underlying difference and a standard deviation of 6.9. The primary analysis will be undertaken on all
patients randomised (intent to treat) alongside per-protocol and complier-average causal effect analyses as
recommended by the extension to the CONSORT statement for non-inferiority trials.
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Discussion: This large-scale trial utilises routinely collected outcome data as well as specific trial data to provide
evidence of the comparative efficacy and cost-effectiveness of Counselling for Depression compared with Cognitive
Behaviour Therapy as delivered within the UK government’s Improving Access to Psychological Therapies initiative.
Trial registration: Controlled Trials ISRCTN Registry, ISRCTN06461651. Registered on 14 September 2014.
Keywords: Depression, Non-inferiority trial, Cognitive behaviour therapy, Counselling for depression
Background
Since 2008, patients presenting to the UK National Health
Service (NHS) with a primary condition of mild, moderate
and severe depression are typically treated within Improv-
ing Access to Psychological Therapies (IAPT) services.
These services are premised on a stepped care model and
built on the argument for improved access to, in particular,
cognitive behaviour therapy (CBT), which resulted in a
large investment in training a new workforce in this par-
ticular psychological approach [1]. The model of stepped
care within the IAPT initiative required a new workforce of
Psychological Wellbeing Practitioners (PWPs) as the
immediate point of contact for patients with mild to
moderate depression (step 2) with the aim of their
providing psycho-educational interventions with the
option of stepping up patients to high-intensity CBT
therapists (step 3) should initial benefits to patients
not be realised. An initial implementation of the
stepped care model was carried out at two demon-
stration sites [2, 3] followed by an expansion to 32
pathfinder sites [4] and then by national rollout.
To date, the IAPT programme has yielded updates from
the Department of Heath [5] as well as evaluations of differ-
ing aspects of the implementation [6]. While the implemen-
tation of IAPT at step 2 and step 3 originally focused only
on training and delivering CBT-based personnel and inter-
ventions, more latterly the provision of psychological
approaches at step 3 has been extended to include bona fide
psychological therapies in addition to CBT, namely interper-
sonal psychotherapy, dynamic interpersonal therapy, couples
counselling, and counselling for depression (CfD), with the
latter being the focus of the present article.
The NICE review of psychological interventions for
depression identified CBT as the front-line psychological
intervention while counselling was assigned to situations
in which first-line interventions were either not success-
ful or were not preferred by the patient on the basis that
the evidence for counselling was ‘uncertain’ [7]. The
robust evidence base for CBT was a key factor in the
UK government’s funding of the IAPT initiative and the
drive to train large numbers of practitioners in CBT as
part of workforce development in Primary Care. While
CfD is, therefore, one of the NICE-recommended psy-
chological therapies for mild to moderate depression
made available within IAPT services, its role is second-
ary to CBT and there is no evidence underpinning its
implementation for patients presenting with more severe
levels of depression.
This article sets out the protocol for a randomised con-
trolled trial embedded within one IAPT service to deter-
mine the relative efficacy of CfD as compared with CBT.
The protocol adheres to the Standard Protocol Items:
Recommendations for Intervention Trials (SPIRIT) check-
list, which is available as an Additional file 1.
Review of existing literature
A review of six RCTs showed patients who were
assigned to counselling demonstrated a significantly
greater reduction in psychological symptoms such as
anxiety and depression than patients receiving usual GP
care when followed up at up to 6 months [8]. These
psychological benefits were modest: the average coun-
selled patient was better off than approximately 60% of
patients in usual GP care. However, there were no
significant differences between counselling and usual
care in the four RCTs reporting longer-term outcomes
(8 to 12 months).
A trial comparing non-directive counselling with CBT
yielded similar outcomes amongst the two therapies in
their overall effectiveness at short- or long-term follow-
up [9]. Both therapies were superior to usual GP care in
the short term but provided no significant advantage in
the long term. Findings from this trial were not included
in the Depression Guidelines because of a significant
proportion of patients having a diagnosis of mixed anx-
iety and depression. However, a subsequent re-analysis
of data focusing only on those patients meeting a diag-
nosis of depression confirmed the earlier results [10].
In a meta-analysis, a comparison of CBT with therapy
similar to counselling (non-directive supportive therapy)
demonstrated no statistically or clinically significant
difference with a small advantage in favour of CBT of d
= 0.05 (95% CI −0.08, 0.18) [11]. However, the authors
commented that this difference is small, its clinical rele-
vance is unclear, and the collection of studies included
under the broad heading of supportive psychotherapy
may have been overly heterogeneous. Further, CBT had
the highest relative risk of drop out (k = 26, RR = 1.16).
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A state-of-the art review of the literature regarding
person-centred and experiential therapies reported that
Person-Centred Therapy (PCT) appeared to be consist-
ently, statistically and practically equivalent in effective-
ness to CBT (22 studies, including 17 RCTs, with effect
sizes of −0.06 and −0.1 respectively [12]. Further,
evidence from practice-based studies indicates that PCT,
as defined by the practitioners and as delivered in the
NHS, is effective and not significantly different from
CBT [13, 14]. In response to the IAPT initiative, a recent
review of data from the 1-year rollout indicated that for
depression, counselling was as effective as CBT [6].
In terms of psychological approaches taken up by adults
experiencing specified levels of depression within the past
week, data released by NHS Digital from the 2014 Office of
National Statistics (ONS) Adult Psychiatric Morbidity
Survey (APMS) identified counselling (including bereave-
ment counselling) as the most used psychological interven-
tion (7.7%) followed by psychotherapy (7.2%) and CBT
(5.6%) [15]. For those adults meeting a specified criterion of
severity (score 18+) on the Clinical Interview Schedule-
Revised [16], the rates for being in receipt of psychological
therapies was highest for CBT (6.5%), followed by counsel-
ling (5.7%) and then psychotherapy (4.5%). These data indi-
cate that generic counselling is a prominent psychological
intervention and that it is also being delivered to adults pre-
senting with more severe levels of depression. Recently
published data for 12 months (2015–16) from the UK na-
tional IAPT programme reports utilisation rates of 152,452
for CBT and 61,414 for CfD. The recovery rates for patients
completing a course of treatment for depression at step 3
(high intensity) were 45.9 per cent for CBT and 47.6 per
cent for Counselling for Depression (CfD) [17].
Hence, the collective evidence from a number of
sources suggests either small differences or broadly
equivalent results when making comparisons between
CBT and counselling (as a broad discipline) as well as
with CfD specifically. However, these results may be due
to a number of factors, for example the heterogeneity of
non-CBT comparators and the over-sampling of mild
depression. There is a recent small pilot feasibility com-
parison between nondirective counselling (not CfD) and
CBT for persistent sub-threshold mild depression that
obtained no difference in findings; however, this is prob-
ably too narrow a severity band to be relevant to typical
depressed populations encountered in counselling and
its associated practitioners [18].
However, there is no robust trial evidence supporting the
use of counselling and, more specifically, CfD with severe
depression. Accordingly, there is a need for a randomised
controlled trial of CfD for moderate and severe depression.
Furthermore, given that CBT is the current treatment of
choice for moderate and severe depression, there is a need
to know the relative efficacy of CfD as compared with CBT
(rather than, for example, a no-treatment condition).
Hence, it is important that all stakeholders have access to
better quality evidence concerning the efficacy and
efficiency of Counselling for Depression (CfD). Further-
more, in terms of ensuring that patients have a choice of
differing talking therapies, establishing the efficacy of CfD is
important.
Pilot work and determining type of trial
In light of the extant literature, there was no basis for
adopting a superiority trial. Analyses of existing Sheffield
IAPT service data (1 April 2009–30 September 2010)
indicated only small differences in outcomes between
CBT and counselling. In the analysis of patients with
PHQ-9 intake scores ≥12 in the Sheffield service data,
the overall mean (SD) pre-last change in PHQ-9 was 6.8
(6.9) and there was no significant difference between
counselling and CBT (difference = +0.5 points on the
PHQ-9 in favour of counselling; 95% CI −0.3, +1.3).
Analysis of a further data set from the same service of
data collected between June 2010 and October 2013
showed a small effect size advantage to CBT of 0.16 with
the extent of pre-post change being 1.0 PHQ-9 point
greater for CBT (7.3) than counselling (6.3) [19]. When
number of sessions and type of therapy ending were en-
tered into the multilevel modelling, treatment modality
was not significant.
From these findings, we predicted the actual difference
in change means between approaches to be close to
zero. However, we were mindful that these data were de-
rived from counselling as delivered in a routine practice
setting and not from CfD. In addition, the aim of the
trial was to underpin the delivery of CfD within the
IAPT service delivery system as a viable alternative to
CBT. Accordingly, we proposed a pragmatic trial and
reasoned that the primary aim of the trial was to test
that CfD as delivered in routine settings was non-
inferior to CBT within an agreed a priori tolerance. The
central tenet of a non-inferiority trial is that the candi-
date treatment does not yield patient outcomes that are
inferior to a benchmark treatment such that would be
clinically notable. Accordingly, we proposed a non-
inferiority trial.
Objectives
The primary objective is to determine the clinical and
cost-effectiveness of CfD compared with CBT as delivered
in primary care for patients presenting with moderate or
severe depression. The secondary aims are to explore
patients’ experiences of the treatments received and, for
those patients who drop out of treatment, to gather infor-
mation as to the reasons. The outcomes of trial patients
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will also be compared to patients within the IAPT service
but who were not participants in the trial.
Methods
Design
The PRaCTICED trial is a pragmatic, two-arm, parallel
group, non-inferiority RCT comparing the clinical effi-
cacy and cost-effectiveness of CfD and CBT within a
local Improving Access to Psychological Therapies
(IAPT) service. The trial utilises all mandated data col-
lected routinely as part of the IAPT service as well as
additional data required by the trial design (see later for
details). This reported version of the protocol conforms
to the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) guidelines. A copy of the
SPIRIT Checklist is contained as part of the supplemen-
tal materials (see Additional file 1).
Participants/inclusion and exclusion criteria
Participants are patients receiving step 2 treatment
within the IAPT service in Sheffield, UK, and who meet
the following inclusion criteria: aged 18 or over and
having been deemed to require stepping up by a Psycho-
logical Wellbeing Practitioner (PWP), a score of 12 or
more on the PHQ-9, with depression as their major
focus for treatment. Patients meeting these general
criteria are invited to a screening assessment to deter-
mine their eligibility for the trial. An initial criterion is
that patients do not have a strong preference such that
they would be unwilling to accept one of the treatments
if they were randomised to it. This is checked by PWPs
and verified at the screening interview.
Other exclusion criteria are: presence of organic con-
dition, psychosis, drug or alcohol dependence, or
elevated clinical risk. Patients may be in receipt of medi-
cation for depression but the regime must be stable at
the point of entry to the trial. If they are in receipt of
medication, this will be recorded.
Study setting
The study is embedded within the Sheffield IAPT ser-
vices, covering potentially 93 GP practices. The popula-
tion of Sheffield is 560,000 people and the city region
has an Index of Multiple Deprivation of 17.9% placing it
as seventh most deprived core city in England. It is
ranked 60th out of 326 in terms of most deprived local
authorities in England and nearly one quarter of the
Lower Super Output Areas are within the most deprived
10% nationally.
The Sheffield IAPT service comprises four distinct
geographical sectors: southeast, southwest, north and
west. It routinely delivers both counselling and CfD
within the step 3 service as well as CBT to patients pre-
senting with depression who have not responded to a
low-intensity treatment (step 2 in the IAPT stepped care
model). CfD counsellors and CBT therapists undertake
their IAPT work within GP practices or at a central
location thereby ensuring that accessibility for patients
receiving treatment in each locality of Sheffield is
optimal.
Psychological interventions
The psychological intervention being evaluated is CfD as
the candidate intervention against Beckian CBT, which
is acting as the comparator benchmark intervention.
Both treatments are currently offered as standard within
the IAPT service.
Counselling for Depression (CfD)
CfD [20, 21] is a form of person-centred/experiential
(PCE) therapy derived from the competences required to
deliver effective humanistic psychological therapies for
depression. CfD is drawn from those humanistic
approaches with the strongest evidence for efficacy,
based on outcomes of controlled trials (for a review, see
[12]). CfD is specifically designed to address depression
and is delivered within IAPT and related programmes.
Whilst counselling has long been available in NHS Pri-
mary Care settings, service design and treatment
approaches in practice have proved very variable.
The CfD curriculum was developed by BACP [the
British Association for Counselling and Psychotherapy,
sponsored by the UK Department of Health (DH)] and
the work of the design team informs this protocol. The
programme trains counsellors to provide a depression-
specific therapy for individual patients (in an IAPT set-
ting where a patient has not responded to low-intensity
intervention or actively opts for counselling). The CfD
competences are outlined in an IAPT-endorsed frame-
work drawn from a number of NICE-endorsed research
studies and from key texts identified by the Humanistic
Psychological Therapies Expert Reference Group that
describe the modality and underpin its effectiveness [22].
Person-centred counselling [23] and emotion-focused
therapy [24] have much in common both theoretically
and in terms of their methods. When used in combin-
ation they are often referred to as person-centred/ex-
periential therapy.
Prior to the trial commencing, we provided CfD training
to all counsellors in Sheffield IAPT that has facilitated a
move towards standardised practice and evidence-based
service evaluation. CfD training standardises counselling
work with depressed patients and aligns therapist inter-
ventions with the evidence-base underpinning NICE
guidelines. The CfD training is aimed at experienced
person-centred and humanistic practitioners as a ‘top-up’
provision. The training consisted of a 5-day taught
programme delivered across a 1 or 2-week block, followed
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by a period of supervised clinical work. During clinical
practice associated with CfD training, a minimum of 80 h
of supervised practice must be completed. Only those
who have completed the training will be included within
the trial, meaning increasing numbers of counsellors will
be included as the trial progresses. The delivery of CfD is
standardised by adoption of the text Counselling for de-
pression: A person-centred and experiential approach to
practice [25]. Manuals based on this text, the CfD theoret-
ical approach and training have been developed and pro-
vided to all counsellors to act as an on-going reference
and training resource [26].
Beckian Cognitive Behavioural Therapy (CBT)
The comparator is high-intensity CBT as delivered
within the Sheffield IAPT service. The curriculum for
high intensity CBT states that CBT is now known to be
an effective treatment option for many problems. In the
NICE guidelines for anxiety disorders and depression
CBT was strongly recommended [7].
CBT within the IAPT service comprises two protocol
driven interventions: Beckian cognitive therapy [27, 28] and
Martell’s behavioural activation [29]. These interventions are
delivered by high-intensity CBT practitioners in accordance
with NICE guidance in which CBT and BA are recom-
mended for the treatment of mild to moderate depression
but only CBT for the treatment of severe depression.
Although the COBRA trial addressed the comparative effi-
cacy of BA versus CBT for depression [30] the comparator
treatment in this trial will be confined to CBT only so as to
ensure clarity of the comparator and to maximise comparison
with other trial evidence using CBT. Representing equal com-
mitment to the comparator treatment, we provide regular
‘top-up’ workshops for all Sheffield IAPT CBT practitioners,
so that all practitioners receive up-to-date training in their re-
spective treatment method prior to and during the trial.
The delivery of CBT is standardised by the adoption of
the text Cognitive behaviour therapy: Basics and beyond
(2nd edition) [28], which is available to all CBT practi-
tioners supporting the trial. In addition, a CBT Manual
has been written, termed a Clinical Practice Guide
(CPG), to guide the delivery of CBT in the trial [31].
This has been based on a similar CPM written for two
recent major UK trials of CBT: CoBaLT and COBRA
[32]. The CPM has been adapted and developed with in-
put from trial co-applicants (SK & GW) and the lead
CBT practitioner in the Sheffield IAPT service. It does
not present any new component of CBT but simply acts
as a reminder to all practitioners to adhere to the treat-
ment model being delivered.
Treatment delivery
Patients are offered a maximum of 20 sessions in either
intervention as this is the maximum number stated for
CBT and for CfD. Accordingly the potential maximum
course of the interventions is similar for both interven-
tions. Patients only discontinue in their assigned inter-
vention if the therapist, following discussion with their
supervisor, considers there are strong clinical grounds
for doing so.
Training in the psychological models
The counsellors are required to complete 80 h CfD
experience in four 20-h blocks with these sessions being
audio-taped. It is standard practice within the IAPT
model of competencies and within Sheffield IAPT for
counsellors (and CBT therapists) to audio-record ses-
sions to receive quality supervision. This is consistent
with the CfD national curriculum.
Practitioners select one tape from each of the four
blocks of 20 tapes submitted to the expert trainers to be
assessed on a developmental trajectory. The final tape
assessment determines their competency as a CfD prac-
titioner. These standards are set out in the IAPT
national document and are, therefore, national standards
that are expected for any person working as a CfD
practitioner.
The CBT practitioners all meet the IAPT training stan-
dards. However, they will be provided with additional
training directed to ensuring that their delivery is consist-
ent with Beckian CBT. Half-day workshops will be deliv-
ered for trial therapists focusing on CBT treatment of
depression and will be led by local experts in CBT.
Clinical supervision and adherence/competency
monitoring
We will monitor and assess adherence and competence
through two methods: clinical supervision and rating of
audiotapes of therapy sessions. The benchmark adher-
ence/competence rating scales for each therapy condition
will be used: for CfD, the Person Centred and Experiential
Psychotherapy Rating Scale (PCEPS) [33] and, for CBT,
the Cognitive Therapy Scale-Revised (CTS-R) [34, 35].
Clinical supervision is carried out as standard in line
with IAPT guidelines, ensuring that only qualified CfD
supervisors supervise CfD-trained counsellors. Supervi-
sors use a simplified four-item version of the Person
Centred and Experiential Psychotherapy Scale (PCEPS)
to monitor adherence together with general competency
at their supervision sessions during the course of the
trial. For any one patient, this is carried out at sessions
2, 6 and 12 (should the patient receive that number of
sessions). This procedure ensures that adherence and
competency data are available for all patients in the trial.
CBT supervision mirrors the CfD process using a simpli-
fied four-item version of the Cognitive Therapy Scale-
Revised (CTS-R) completed by the supervisor at sessions
2, 6 and 12. These session forms are referred to as the
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Session Adherence and Competence Scale (SACS) for
CfD (SACS-CfD) and for CBT (SACS-CBT).
Treatment fidelity
Regarding assessing treatment fidelity, our strategy is to
ensure that tapes from each practitioner are sampled to
establish that each treatment arm is being delivered
according to the specified standard. The procedures for
assessing treatment fidelity will be identical for both in-
terventions. The description here applies to each inter-
vention arm. The raters for the two interventions will be
independent to minimise contamination.
Stage 1 (Calibration): A sample of five tapes (one from
five practitioners selected at random) for each
intervention will be rated by national experts to
provide a target rating to be used in the training and
standardisation of subsequent ratings. The national
rater(s) for CfD will be based at the University of York
St John and for CBT at the Oxford Cognitive Therapy
Centre (OCTC).
Stage 2 (Independent fidelity ratings): Digital recordings
of sessions will be selected at random using the
following procedure. At the therapist level, for each
therapist, one case will be selected at random per block
of five seen cases (or upwards of 5). Hence, the
sampling strategy ensures that (1) all therapists are
sampled and (2) the pool of rated tapes and overall
competence ratings reflect the differential loading
carried by therapists. At the session level, for each case
sampled, the selected session will be randomly selected
from early (excluding session 1), middle or late
(excluding final session). This sampling strategy will
yield a total of 50 tapes per intervention, thereby
providing a total of approximately 100 tapes to be rated
in the trial (although the actual number may vary as a
function of numbers of therapists and the number of
sessions delivered).
Stage 3 (Independent fidelity audit): As a final check, a
small subsample of the independent fidelity ratings will
be audited by experts in the respective therapies.
Patient consent process
PWPs are the initial point of contact and gatekeepers for
entry into the trial (i.e., there is no direct GP referral or
self-referral into the trial). PWPs utilise both face-to-face
as well as telephone assessments of patients in their
work. If the PWP considers that, during their initial
assessment of the patient or their subsequent work with
them, the trial would be an appropriate course of treat-
ment, then they introduce the trial and request consent
for the research team to contact them. Appropriateness
for the trial is that a patient’s PHQ-9 score is 12 or
higher and that they present with depression and wish
to be treated for depression. Ethics approval has also
been given for this procedure to be carried out over the
telephone. Potential participants are then sent informa-
tion on the trial and a Consent to Treatment form
together with an appointment date for an assessment
interview.
The PWP contacts the patient 2–4 days before the
screening appointment to answer any questions about the
trial and check that the patient is still willing to attend the
screening. Should the patient not wish to proceed with the
trial, the PWP will carry out the usual procedures for non-
trial patients. At the screening appointment, the patient
has the opportunity to ask any further questions before
signing consent forms to enter the trial. They are also
provided with contact information and consent to be
contacted by researchers in the future.
Diagnostic assessment
Patients attending the assessment interview are asked
again whether they have a strong preference for one or
the other treatment such that they would refuse a treat-
ment if it were offered to them. The primary measure
for determining suitability for the trial is the Clinical
Interview Schedule-Revised (CIS-R) with the require-
ment that patients meet an ICD-10 diagnosis of moder-
ate or severe depression [16]. Assessment interviews are
carried out either by Clinical Support Officers (CSOs) or
members of the research team. All assessors are trained
in using the CIS-R. If active thoughts of suicide are indi-
cated from the CIS-R, we implement a risk protocol to
inform the PWP or identified practitioner. In terms of
alcohol or substance dependency, these are determined
by specific questions from Section I (Alcohol) and
Section II (Drug) of the Mini-International Neuropsychi-
atric Interview (M.I.N.I.) [36], which yield diagnoses of
current alcohol or drug dependency. If a patient meets
an ICD-10 diagnosis of moderate or severe depression,
they are consented into the trial. Patients who do not
meet the criterion are talked through the reasons and re-
ferred back to the PWP. Figure 1 presents a flow study
chart of the progress of patients through the trial.
Randomisation
Consenting patients are allocated to one of the two
treatment arms via remote access to the randomisation
procedure that is hosted by epiGenesys, a wholly owned
subsidiary of the University of Sheffield.
Blinding
Allocation to either intervention is recorded in a separ-
ate location in the patient data log. The assessors carry-
ing out the therapy exit interviews do not have
immediate access to information regarding allocation
assignment. Statisticians conducting the analysis will not
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be involved in the administration of the trial and will be
blinded to the randomisation. Key variables (i.e., treat-
ment assignment) will be coded as non-identifiable vari-
ables to minimise potential biasing in analyses. Blinding
of a patient’s assignment to treatment will only be
unmasked on the specific direction of the Data Manage-
ment and Ethics Committee.
Measures
Patients then complete the second part of the assess-
ment interview comprising the completion of a battery
of measures. All assessors receive a standard training re-
garding the collection of assessment data. A summary of
the assessments is presented in Fig. 2.
Treatment Preferences and Credibility
Patient preferences and credibility regarding the two
interventions are measured using standard scales
adapted to the specific interventions [37, 38].
Primary Outcome
Patient Health Questionnaire-9 (PHQ-9) [39] The
primary outcome measure is the PHQ-9, a brief (9-item)
self-report 4-point Likert-type scale measure of depres-
sion. Items correspond to each of the nine DSM-5
criteria for depression [40]. Items ask patients to rate
how often they have been affected by symptoms (of
depression) over a 2-week time period prior to complet-
ing the questionnaire.
Fig. 1 Study flow diagram of referral, screening and allocation of patients to the PRaCTICED trial. Legend: BDI-II Beck Depression Inventory II, CSQ
Client Satisfaction Questionnaire, CD-RISC Connor-Davidson Resilience Scale, CIS-R Clinical Interview Schedule-Revised, CSRI Client Service Receipt
Inventory, CORE-OM Clinical Outcomes in Routine Evaluation-Outcome Measure, EQ-5D-5L Euroqol 5D-5L, GAD-7 Generalised Anxiety Disorder-7,
MINI Mini International Neuropsychiatric Interview, PHQ-9 Patient Health Questionnaire-9, QoLS Quality of Life Scale, WSAS, Work and Social
Adjustment Scale
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Individual item scores range from 0 (“not at all”) to
3 (“Nearly every day”) with total PHQ-9 scores ran-
ging from 0 to 27. Scores of 10 and above are demar-
cated as clinical scores. Scores of 5–9, 10–14, 15–19
and 20–27 are classified as reflecting mild, moderate,
moderately severe and severe levels of depression re-
spectively. The measure has an internal reliability of
0.89 and a test-retest reliability of 0.84 across 48 h.
The PHQ-9 is mandated by the IAPT service and is
completed by patients at each session attended along
with other mandated measures within the IAPT mini-
mum data set (MDS) [41].
Secondary Outcome Measures
A range of secondary outcome measures is collected. At
baseline, the intensity of depression is measured via the
Beck Depression Inventory-II (BDI–II) [42], psycho-
logical distress via the Clinical Outcomes in Routine
Evaluation-Outcome Measure (CORE-OM) [43], gener-
alised anxiety via the Generalised Anxiety Disorder
Assessment (GAD-7) [44], plus the Work and Social
Adjustment Scale (WSAS) [45]. Mobility, self-care,
usual activities, pain/discomfort and anxiety/depression
are measured via the EQ-5D-5L [46, 47] and Quality of
Life Visual Analogue Scale (QoLS) (personal communi-
cation: J. Connell). In addition, patients complete the
Connor-Davidson Resilience Scale (CD-RISC) [48].
Patient service receipt data are also collected [49]. At
6- and 12-month follow-ups, in addition to the PHQ-9
as the primary outcome, the BDI-II, CORE-OM, GAD-
7, WSAS, EQ-5D-5L, QoL and CSRI are collected, as is
the Client Satisfaction Questionnaire (CSQ) [50].
Fig. 2 SPIRIT diagram of assessments at enrolment, allocation, weekly sessions, and 6- and 12-month time points Legend: BDI-II Beck Depression
Inventory II, CD-RISC Connor-Davidson Resilience Scale, CIS-R Clinical Interview Schedule-Revised, CSRI Client Service Receipt Inventory, CSQ Client
Satisfaction Questionnaire, CORE-OM Clinical Outcomes in Routine Evaluation-Outcome Measure, EQ-5D-5L Euroqol 5D-5L, GAD-7 Generalised
Anxiety Disorder-7, MINI Mini International Neuropsychiatric Interview, PHQ-9 Patient Health Questionnaire-9, QoLS Quality of Life Scale, WSAS,
Work and Social Adjustment Scale
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Four weeks after a patient ends treatment, either
through completing or dropping out from sessions, they
are contacted to undertake a brief questionnaire/short
interview (telephone, face-to-face or web-based) to
collect data on their experiences of the treatments.
Sample Size
Published findings [2–4] and Sheffield IAPT service data
(1/4/09 – 30/9/10) indicate only small differences in out-
comes between CBT and counselling. Hence, from these
findings we predict the actual difference in mean change
between treatments to be zero. Accordingly, the margin
within which CBT could not be considered statistically
or clinically more effective than CfD was determined as
follows: First, treatment effects of 0.2 to 0.3 are conven-
tionally viewed as ‘small’ and of limited clinical value
(e.g., [51, 52]). Second, it has been recommended that
the threshold for non-inferiority be set at 50% or less
than the expected difference between CBT and usual
care, which would mean an effect size of less than 0.3
(i.e., 0.6/2). Finally, discussions with psychologists on the
research team and IAPT staff indicated that less than 2
points on the PHQ-9 is not perceived as clinically
important, which is equivalent to an effect size of just
under 0.3 (given the pre-last SD of 6.9 found in the ser-
vice data above). Therefore, a pre-last change difference
of less than 2 on PHQ-9 in favour of CBT was adopted
as the limit for non-inferiority of CfD.
It is estimated that 550 patients (275 per arm)
would need to be recruited to the trial to secure the
500 patients needed to test the non-inferiority hy-
pothesis at the one-sided 2.5% significance level with
a power of 90%. This assumes a standard deviation of
6.9 (derived from the aforementioned service use
data, which incorporate both inter-patient and inter-
therapist variability), no underlying difference between
the effect of CBT and counselling and a 10% loss to
6-month follow-up. As the trial is within a service
with few additions to routine practices and proce-
dures, it is expected that relatively few participants
will leave the trial and not provide a 6-month follow-
up PHQ-9. To sustain adequate referrals via PWPs,
weekly monitoring of referral rates in each sector oc-
curs together with monthly feedback via sector man-
agers as well as target setting.
Data management
Data entry will be checked using a 5% double-entry proced-
ure. Anonymised measures data are stored electronically on
a University of Sheffield password-protected secure server,
with only named people having access. No patient personal
details are stored electronically. Paper copies of measures
are stored in locked filling cabinets behind two locked doors.
Patient contact information, on paper, is stored in different
locked filling cabinets, in a different office, again behind two
locked doors. The trial adheres to the University of Sheffield
Ethics Policy Governing Research Involving Human Partici-
pants, Personal Data and Human Tissue (version 6). Infor-
mation Governance toolkit details for electronic data
storage are as follows: organisation code 8D715-SHR, ver-
sion 13, 2015/16; reviewed grade satisfactory (level 2 or
above).
Statistical methods
Statistical analyses will be carried out by a statistician and se-
nior statistician from the Clinical Trials Research Unit
(CTRU). Neither will be involved in the administration of the
trial and both will be blinded to the randomisation and as-
signment. The two treatment arms will be coded as non-
identifiable variables to minimise potential biasing in analyses.
Primary analysis
The primary analysis will adhere to a Statistical Analysis
Plan (SAP) devised by an independent statistician under the
guidance of the senior medical statistician. The SAP was
informed by the International Conference on Harmonisa-
tion topic E9 [53], reference to the literature (e.g., [54])
and applicable standard operating procedures from the
University of Sheffield Clinical Trials Research Unit
(CTRU). Non-inferiority of counselling to CBT will be
concluded if the CI lies entirely above the non-inferiority
limit of −2 units (i.e., that a difference as large as 2 units
in favour of CBT has been ruled out).
In contrast to superiority trials, the ITT analysis is anti-
conservative (i.e., it underestimates the treatment effect)
when looking at non-inferiority. Specifically, if an inter-
vention is not delivered as fully planned by the protocol
the ITT analysis dilutes the treatment difference and
therefore raises the risk of having the groups look artifi-
cially similar (and hence CfD being artificially non-inferior
to CBT). Given the pragmatic nature of the trial the ITT
will remain the primary analysis population, but additional
consideration will be given to other analyses that exclude
participants who did not receive the intervention as
planned. It should also be noted there is a general lack of
guidance regarding the choice of the primary analysis
population for non-inferiority trials [55].
The additional analysis populations are:
1) An objective per-protocol analysis (PP1) that excludes
participants who receive fewer than four sessions
within 6 months of randomisation and/or who switch
treatment arms within 6 months of randomisation.
2) A case-review per-protocol analysis (PP2) in which
participants are assessed on a case-by-case basis for the
number and timing of sessions, additional therapies
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received and therapist adherence to principles of CBT
or CfD. This will necessarily be unblind to treatment
group but will be blind to outcome data.
3) Complier-adjusted causal effect (CACE) models in
which participants who undergo their intervention in
accordance with protocol are compared to those in the
comparator group who are “likely” to have done so
(based on statistical modelling) had they been
randomised to receive it. Two CACE analyses will be
undertaken, one of which excludes “non-receivers” of
CBTand the second removing “non-receivers” of CfD.
A fuller description of these analyses is provided in the
Statistical Analysis Plan.
Secondary analysis
This will consider baseline to 6-month and baseline to 12-
month change in PHQ-9, BDI-II, CORE-OM, GAD-7,
WSAS, and EQ-5D-5L and QoLS using the same method-
ology as for the primary outcome measure. Similarly,
change from baseline to the routinely collected end of ther-
apy score on PHQ-9, GAD-7 and WSAS will be analysed.
The proportions of patients making reliable and clinically
significant change [56, 57] on PHQ-9, BDI-II, CORE-OM
and GAD-7 will also be compared. Additional exploratory
analyses will be used to identify characteristics of patients
and therapists that are predictive of better outcomes overall
and within each therapy. In addition, the reasons why
patients leave therapy prematurely and the experiences of
patients who remain in or leave therapy will be investigated.
Consideration will also be given to the number and effect
on outcome of patients experiencing sudden gains in each
treatment arm.
Routine service data for patient cohort
For the period spanning patient recruitment into the
trial (approximately 36 months), all patients who are
stepped up to step 3 will define the patient cohort within
which the trial is embedded. Data collected routinely as
part of the service for non-trial participants will be made
available in anonymised form as a comparator. These
data will provide added value in terms of external valid-
ity and will allow comparisons to be made between trial
participants and non-participants, in order to consider
the representativeness of our research sample. The abil-
ity to derive this comparison addresses a key limitation
of trials methodology in terms of external validity.
Given that the primary outcome measure is standard
throughout IAPT services, the outcomes of trial and
non-trial patients can be compared with those from
published literature on counselling and CBT within rou-
tine IAPT services [2–4, 58]. This approach does not
place any additional burden on non-trial participants, as
the measures they complete are routine and mandatory
as part of the IAPT service agreement. Further, it does
not add cost to the proposed study and therefore is clear
added value. In addition, as the data will contain
sessional PHQ-9 scores including a last session attended
(end of therapy) score, it will be used in conjunction
with trial data for further analyses.
Missing data
By recruiting sufficient numbers to account for trial
dropout to 6-month follow-up, it is planned that primary
endpoint data will be adequate to address the main
research question. Routinely collected PHQ-9 scores will
be available for sessions attended prior to dropout, and
these will be used as part of the imputation process
where the 6-month endpoint data are missing. It is
expected that 80% of patients who have competed treat-
ment will provide research data at 12 months post-
randomisation. Isolated instances of missing data will be
imputed by linear interpolation. Multiple imputation
methods will be used for patients with more substantial
missing data, and the sensitivity of the results will be
further assessed by imputing alternative values based on
the reason for dropout.
Economic analysis
We will establish the cost-effectiveness of CfD compared
to CBT [59]. The purpose is to establish what the
additional benefit and resource implications of CfD are
relative to CBT. The primary analysis will be from a
health and social care perspective and will therefore in-
clude costs to the NHS and social care services. The
method used to conduct this economic analysis will
depend on treatment outcomes.
Where treatment outcomes are found to be equivalent
based on the primary measure of efficacy, a cost mini-
misation analysis will be conducted. In this case, the
focus will be in assessing any cost differences between
CfD and CBT.
Total costs of each intervention will be estimated
using the number of sessions multiplied by national unit
costs and data from the local Trust. The consequences
for the use of other health and social care resources
(including hospital admissions, outpatient attendance,
GP visits, other therapy and medication) will be mea-
sured using a patient-completed resource use question-
naire and service data and costed with national unit
costs. Individual level mean costs (intervention and
other resource use) for CfD and CBT will be compared;
uncertainty around the costs estimates will be generated
using probability sensitivity analysis. One-way sensitivity
analysis will be conducted on key assumptions such as
the number of sessions.
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Where one intervention proves to be more effective,
then a cost-effectiveness analysis (CEA) will be under-
taken using the estimated incremental cost per quality
adjusted life year (QALY), that is, the difference in
outcomes divided by the difference in costs for CfD
and CBT. The primary outcome measure for the CEA
will be the EQ-5D-5L. The EQ-5D-5L is a generic
preference-based measure of health designed for cal-
culating QALYs. It is composed of five dimensions:
mobility, self-care, usual activities, pain/discomfort
and anxiety/depression, each with five levels describ-
ing 3125 health states in total. The EQ-5D-5L is a re-
vision of the EQ-5D, the NICE recommended
measure for economic evaluation, offering better
sensitivity [46]. The EQ-5D-5L has been valued by
the general public in England and we will apply these
new values to generate utility values [60]. QALYs will
be estimated from the EQ-5D-5L collected from pa-
tients at baseline, 6 and 12 months. Individual patient
level data on costs and QALYs over 12 months will
be used to estimate the mean cost-effectiveness of
CfD compared to CBT and the underlying uncertainty
around it by a probabilistic sensitivity analysis.
One-way analysis of key assumptions will be under-
taken and where differences persist at 12 months
then the analysis will be extrapolated beyond
12 months. Additional analysis will include assessing
outcomes for CfD compared to CBT in terms of the
proportion who achieve reliable and clinically signifi-
cant improvement based on the PHQ-9 [56, 57].
Patients will be classified as having had a reliable and
clinically significant improvement if they change by 6
points and move from a clinical population at base-
line (10 and above) to a non-clinical population (9
or less) at 12 months. This will be combined with
incremental costs to establish the incremental costs
associated with reliable and clinically significant
improvements.
Process Analyses
To achieve a fuller understanding of patients’ experi-
ences of CBT and CfD and how these impact of the
course of treatment, we will carry out a programme of
process studies using a defined sampling frame compris-
ing cases of therapy non-completion and accounts of
positive change (based on questionnaire returns and se-
lective interviews); patient engagement, resilience and
therapeutic alliance (based on a subsample of routinely
collected tapes); and the phenomenon of sudden gains
and deteriorations (based on routinely collected ses-
sional PHQ-9 scores). We will also be investigating ther-
apy non-completion and accounts of change through
telephone or face-to-face interviews with consenting
participants who have dropped out of therapy.
Risk procedures and reporting of adverse events
We follow standard operating procedures in relation to
assessing patient risk and reporting and acting upon ser-
ious adverse events. All associated research staff are
trained in the recognition of and response to distress
and risk. Written protocols are followed, based on the
standard operating procedures of the Clinical Trials
Research Unit (CTRU), which are consistent with the
Trust procedures within which framework we work.
Public and patient involvement panel
A panel of service users and people with lived experien-
ce—the Public and Patient Involvement (PPI) Panel—has
been established to advise on the strategy, implementa-
tion and future analysis of the data. One of the grant
holders is a person with lived experience. Members of
the PPI panel have been co-opted onto the Trials Steer-
ing Committee as well as the Trials Management Group.
The panel is informed by recent guidance on PPI
involvement [61]. The PPI panel meets approximately
every 4 months to discuss issues arising from the imple-
mentation of the trial. Views and suggestions are fed
back into the TSC and TMG agendas as a standing item.
The PPI involvement is being extended to include
patients who have completed the trial and who are able
to provide input and feedback on its potential benefits.
Confidentiality
Names of participants on the consent forms are stored
separately from data in locked filing cabinets and only
accessible by named personnel. A separate key linking
names to ID numbers used in data files is stored in a
password-protected file on a secure server and only
accessible by named personnel.
Governance and oversight of the trial
A Trials Steering Committee (TSC) has been established
with an independent Chair and comprises representa-
tives from differing professional groups together with
members of the research team. A Data Monitoring and
Ethics Committee (DMEC) has been convened under an
independent chair with statistical expertise together with
two independent clinicians. A data analyst independent
of the trial provides closed reports to the DMEC for
scrutiny of adverse events and any trends in the out-
comes that would suggest it to be unethical to continue
the trial. The chair of the DMEC provides a closed re-
port to the Chair of the TSC. Any decision to stop the
trial rests with the independent members of the TSC. In
addition, a Trial Management Group (TMG) has been
established comprising the research team and key local
personnel involved in the trial with the purpose of
checking operational procedures. The TMG is chaired
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by the lead investigator. A site file is maintained and
constantly updated with all associated documentation.
Discussion
The PRaCTICED trial is a large-scale (and may be the
only) randomised trial investigating the efficacy of CfD
against CBT. Extensive evidence exists for the efficacy of
CBT but the evidence for other psychological therapies
lags behind. Determining the relative efficacy of other
bona fide therapies is important for all stakeholders. The
non-inferiority design adopts a realistic approach to such
a comparison in the context of a pragmatic trial nested
within an existing NHS IAPT service. Advantages of an
embedded trial include having access to routinely
collected outcome measures as well as the additional
measures required specifically by the trial. The routinely
collected data include weekly-administered outcome mea-
sures, including the primary outcome measure (PHQ-9).
Not only does this increase the likely response rate in
terms of the primary outcome, but it also provides the
additional level of repeated weekly measurement on the
primary outcome measure across the course of treatment.
Hence, the data collection demand on trial patients is only
proportionately greater than for non-trial patients receiv-
ing therapies within the routine IAPT service. Further
additional advantages of the trial utilising a routine service
lies in having access to larger number of therapists. While
the exact total number will not be known until the trial is
completed, the aspiration is to have in the region of 30
therapists in total delivering interventions in the trial. As
such, this will provide a minimum level in order to be able
to investigate therapist effects.
However, carrying out trials within routine service set-
tings has considerable challenges. One specific challenge
has been the scaling up of sufficient numbers of counsel-
lors trained in the CfD model. Given the part-time na-
ture of the profession, training has been slow. In
addition, attempting to train all existing counsellors in
the service assumed that they would all embrace the
CfD model, an assumption that has had to be adjusted
(unpublished observations: A. Nye, J. Connell, M. Bark-
ham). In terms of the availability of both interventions
at GP surgeries, this has proved to be a challenge. How-
ever, the issue has been largely resolved by the addition
of a central wait list resourced by available trial thera-
pists [62]. At an organisational level, the requirement for
prioritising and implementing a rigorous trial amidst the
realities of an NHS IAPT service delivering therapies
under ever-increasing national performance targets and
annual cost efficiencies is a major challenge. This has
necessitated generating innovative and flexible partner-
ship models between the research team and service
organisation. For example, a key decision has been the
part-time secondment of a PWP working in the service
to the trial research team, thereby enabling a highly
effective link between the research team and both NHS
services and IT systems [63].
On completion of data collection and subsequent ana-
lyses, the findings from the trial will make a significant
contribution to the evidence base for Counselling for
Depression as contrasted with CBT, which is considered
the front-line psychological intervention for depression.
As such, the findings will be of importance to all stake-
holders, whether they are commissioners purchasing ser-
vices, practitioners delivering therapies, or patients
seeking a choice and receiving such interventions.
Trial Status
The study commenced recruitment in October 2014 and
patient recruitment is on-going.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOC 123 kb)
Abbreviations
BDI-II: Beck Depression Inventory II; CACE: Complier-adjusted causal effect;
CBT: Cognitive behaviour therapy; CD-RISC: Connor-Davidson Resilience Scale;
CfD: Counselling for depression; CIS-R: Clinical Interview Schedule-Revised;
CORE-OM: Clinical Outcomes in Routine Evaluation-Outcome Measure;
CSQ: Client Satisfaction Questionnaire; CSRI: Client Service Receipt Inventory;
CTS-R: Cognitive Therapy Scale-Revised; EQ-5D-5L: Euroqol 5D-5L; GAD-
7: Generalised Anxiety Disorder-7; IAPT: Improving Access to Psychological
Therapies; ITT: Intention to treat; MINI: Mini International Neuropsychiatric
Interview; NHS: National Health Service; PCEPS: Person-Centred and Experiential
Psychotherapy Scale; PHQ-9: Patient Health Questionnaire-9; PP: Per-protocol;
PPI: Public and patient involvement; PRaCTICED: Pragmatic Randomised
Controlled Trial assessing the non-Inferiority of Counselling and its Effectiveness
for Depression; SACS-CBT: Session Adherence and Competence Scale-CBT;
SACS-CfD: Session Adherence and Competence Scale-CfD; WSAS: Work and
Social Adjustment Scale
Acknowledgements
We thank members of the Scientific Committee of the BACP Research
Foundation for their support, as well as the Chairs and members of the Trials
Steering Committee, the Data Management and Ethics Committee, the Trials
Management Group, the Public and Patient Involvement Panel and Sheffield
Health and Social Care NHS Foundation Trust. In particular, we thank the
following: Christopher Allsopp, Nicholas Bell, Simon Bennett, Paul Bliss,
Aimee Card, Lorna Carrick, Charlotte Colbeck, Abby Constantine, Helen
Corcoran, Jo Cullen, Joan Davies, Keith Elliott, Laura Flight, Rinda Haake,
Penny Harvey, Jo Hemmingfield, Andy Hill, Trish Hobman, Joe Hulin, John
Kay, Tim Kendall, Helen Kennerley, Karen Kilner, Diane Kinnear, Helen Knight,
Mark Knowles, Lynne Lacock, Penny Merrett, Jodie Millington, Jo-Ann Pereira,
Sue Ridgway, Kate Rosen, Pete Sanders and Karen Sibly.
Availability of data and materials
Supporting data sets are currently unavailable.
Authors’ contributions
MBkm and DS co-conceived the trial, drafted the study protocol, and obtained
ethics and NHS R&D approvals, along with LB-E. KA coordinated the interface
between the trial and NHS service together with SO. PB, MK and SP advised and
contributed to the trial design. JB and CM designed the economic components.
GEH contributed to the overall design and conceived and designed process
Saxon et al. Trials  (2017) 18:93 Page 12 of 14
components of the trial. JC and PH designed qualitative components while JC
and SS coordinated public and patient involvement elements. MBr designed the
statistical analysis and oversaw the Statistical Analysis Plan. LG, RE, SK and GW
advised on and supported the clinical interventions and the writing of practitioner
manuals. TM oversaw NHS service elements and organisation. DS and MBkm
drafted the article and all authors read, edited where necessary and approved the
final manuscript.
Competing interests
MBkm was a member of the research team that developed the CORE-OM and is
a member of the BACP Research Committee. LG was a past Chair of BACP (term
completed prior to the proposal of the trial). MK was a member of the BACP
Research Foundation Scientific Committee (in absentia regarding decisions
concerning the trial). SP was Joint Director, National Collaborating Centre for
Mental Health, who developed clinical guidelines for NICE and continues to
receive funding from NICE for the production of clinical guidelines. All other
authors declare they have no competing interests.
Consent for publication
Not applicable.
Author details
1Health Services Research, Centre for Psychological Services Research, School
of Health and Related Research, University of Sheffield, 30 Regent St,
Sheffield S1 2DA, UK. 2Clinical Psychology Unit, Centre for Psychological
Services Research, University of Sheffield, Sheffield S10 2TN, UK. 3Department
of Psychology, University of Sheffield, Sheffield S10 2TN, UK. 4Health Services
Research, School of Health and Related Research, University of Sheffield, 30
Regent St, Sheffield S1 4DA, UK. 5Sheffield IAPT (Sheffield Health & Social
Care NHS Foundation Trust), St George’s Community Health Centre, Winter
Street, Sheffield S3 7ND, UK. 6Health Economics and Decision Science, School
of Health and Related Research, University of Sheffield, 30 Regent St,
Sheffield S1 2DA, UK. 7NIHR School for Primary Care Research, University of
Manchester, Manchester M13 9PL, UK. 8Clinical Trial Research Unit, School of
Health and Related Research, University of Sheffield, 30 Regent St, Sheffield
S1 2DA, UK. 9Counselling Unit, School of Psychological Sciences and Health,
University of Strathclyde, Room 507, Graham Hills Building, 40 George Street,
Glasgow G1 1QE, UK. 10School of Psychological and Social Sciences, York St
John University, Lord Mayor’s Walk, York YO31 7EX, UK. 11Division of
Psychiatry, Faculty of Brain Sciences, University College London, Sixth Floor,
Maple House, 149 Tottenham Court Rd, London W1T 7NF, UK. 12Research
Department of Clinical Health and Educational Psychology, University
College London, 1-19 Torrington Place, London WC1E 7HB, UK. 13c/o Mental
Health Group, Health Services Research, School of Health and Related
Research, University of Sheffield, 30 Regent St, Sheffield S1 2DA, UK.
14Department of Psychology, Clinical Psychology Unit, University of Sheffield,
Sheffield S10 2TN, UK.
Received: 13 December 2016 Accepted: 9 February 2017
References
1. Layard R. The case for psychological treatment centres. BMJ. 2006;332:1030.
2. Clark DM, Layard R, Smithies R, Richards DA, Suckling R, Wright B. Improving
access to psychological therapy: initial evaluation of two UK demonstration
sites. Behav Res Ther. 2009;47:910–20.
3. Parry G, Barkham M, Brazier J, Dent-Brown K, Hardy G, Kendrick T, Rick J,
Chambers E, Chan T, Connell J, Hutten R, de Lusignan S, Mukuria C, Saxon
D, Bower P, Lovell K. An evaluation of a new service model: Improving
Access to Psychological Therapies demonstration sites 2006–2009. 2011.
Final report. NIHR Service Delivery and Organisation programme.
4. Glover G, Webb M, Evison F. Improving Access to Psychological Therapies:
A Review of Progress Made by Sites in the First Roll-Out Year. Stockton on
Tees: North East Public Health Observatory; 2010. Available at http://
webarchive.nationalarchives.gov.uk/20160302154833/, http://www.iapt.nhs.uk/
silo/files/iapt-a-review-of-the-progress-made-by-sites-in-the-first-roll8208-out-
year.pdf.
5. Department of Health. CSIP. Ways of Working for Everyone: A best practice
implementation guide. 2007.
6. Gyani A, Shafran R, Layard R, Clark DM. Enhancing recovery rates: Lessons
from one year of IAPT. Behav Res Ther. 2013;51:597–606.
7. National Institute for Health and Clinical Excellence (NICE). Depression:
treatment and management of depression in adults. Clinical Guideline 90.
London: National Institute for Health and Clinical Excellence; 2009. Available
at www.nice.org.uk.
8. NHS Centre for Reviews and Dissemination. Counselling in primary care.
Effectiveness matters 2001;5:(2). Available at: https://www.york.ac.uk/crd/
publications/archive/.
9. King M, Sibbald B, Ward E, Bower P, Lloyd M, Gabbay M, Byford S.
Randomised controlled trial of non-directive counselling, cognitive-
behaviour therapy and usual general practitioner care in the management
of depression as well as mixed anxiety and depression in primary care.
Health Techno Asses. 2000;4(19).
10. King M, Marston L, Bower P. Comparison of non-directive counselling and cognitive
behaviour therapy for patients presenting in general practice with an ICD-10
depressive episode: a randomized control trial. Psychol Med. 2014;44:1835–44.
11. Cuijpers P, van Straten A, Andersson G, van Oppen P. Psychotherapy for
depression in adults: a meta-analysis of comparative outcome studies.
J Consult Clin Psychol. 2008;76:909–22.
12. Elliott R, Greenberg LS, Watson JC, Timulak L, Freire E. Research on humanistic-
experiential psychotherapies. In M.J. Lambert (Ed.), Bergin & Garfield’s
handbook of psychotherapy and behavior change, 6th Edition. Hoboken:
Wiley; 2013.
13. Stiles WB, Barkham M, Twigg E, Mellor-Clark J, Cooper M. Effectiveness of
cognitive-behavioural, person-centred, and psychodynamic therapies as
practiced in UK National Health Service settings. Psychol Med. 2006;36:
555–66.
14. Stiles WB, Barkham M, Mellor-Clark J, Connell J. Effectiveness of cognitive-
behavioural, person-centred, and psychodynamic therapies in UK primary care
routine practice: Replication with a larger sample. Psychol Med. 2008;38:677–88.
15. Lubian K, Weich S, Stansfeld S, Bebbington P, Brugha T, Spiers N, McManus
S, Cooper C. Mental health treatment and services. In: McManus S,
Bebbington P, Jenkins R, Brugha T, editors. Mental health and wellbeing in
England: Adult Psychiatric Morbidity Survey 2014. Leeds: NHS Digital; 2016.
16. Lewis G. Assessing psychiatric disorder with a human interviewer or a
computer. J Epidemiol Community Health. 1994;48:207–10.
17. Community and Mental Health team. Psychological Therapies: Annual
report on the use of IAPT services England, 2015–16. NHS Digital;2016.
Available at content.digital.nhs.uk/catalogue/PUB22110/psych-ther-ann-rep-
2015-16.pdf.
18. Freire E, Williams C, Messow C-M, Cooper M, Elliott R, McConnachie A, Walker
A, Heard D, Morrison J. Counselling versus low-intensity cognitive behavioural
therapy for persistent sub-threshold and mild depression (CLICD): a pilot/
feasibility randomised controlled trial. BMC Psychiatry. 2015;15:197.
19. Saxon D, Firth N, Barkham M. The relationship between therapist effects and
therapy delivery factors: Therapy modality, dosage, and non-completion.
Adm Policy Ment Hlth. 2016. Advanced online publication.
20. Pearce P, Sewell R, Hill A, Coles H. Counselling for depression. Ther Today.
2012;23:20–23.
21. Hill A. Curriculum for counseling for depression: Continuing professional
development for qualified therapists delivering high intensity interventions.
Lutterworth: 2011. BACP. Available at http://webarchive.nationalarchives.gov.
uk/20160302154833/, http://www.iapt.nhs.uk/silo/files/curriculum-for-
counselling-for-depression.pdf.
22. Hill A. The competences required to deliver effective Counselling for
Depression (CfD). Lutterworth: BACP. 2011. Available at https://www.ucl.ac.
uk/pals/research/cehp/research-groups/core/pdfs/Counselling_for_
Depression/Depression_Counselling_for_depression_clinician_s_guide.pdf.
23. Mearns D, Thorne B. Person-centred counselling in action. 3rd ed. London:
Sage Pubs; 2007.
24. Elliott R, Watson JC, Goldman RN, Greenberg LS. Learning emotion-focused
therapy: The process-experiential approach to change. Washington DC: APA; 2004.
25. Sanders P, Hill A. Counselling for depression: A person-centred and
experiential approach to practice. London: SAGE Publications; 2014.
26. PRaCTICED Trial Team. Counselling for Depression (CfD) PRaCTICED manual.
Version 2.0. Centre for Psychological Services Research, University of
Sheffield; 2014. Available from the corresponding author.
27. Beck AT, Rush JA, Shaw BF, Emery G. Cognitive therapy of depression. New
York: The Guilford Press; 1979.
28. Beck JS. Cognitive therapy: Basics and beyond. 2nd ed. New York: Guilford; 2011.
29. Martell CR, Addis ME, Jacobson NS. Depression in context: Strategies for
guided action. New York: Norton and Co.; 2001.
Saxon et al. Trials  (2017) 18:93 Page 13 of 14
30. Richards DA, Ekers D, McMillan D, Taylor RS, Byford S, Warren FC, Barrett B,
Farrand PA, Gilbody S, Kuyken W, O'Mahen H, Watkins ER, Wright KA, Hollon
SD, Reed N, Rhodes S, Fletcher E, Finning K. Cost and outcome of behavioural
activation versus cognitive behavioural therapy for depression (COBRA): a
randomised, controlled, non-inferiority trial. Lancet. 2016;388:871–80.
31. PRaCTICED Trial Team. Cognitive Behaviour Therapy (CBT) PRaCTICED
manual. Version 2.0. Centre for Psychological Services Research, University of
Sheffield; 2014. Available from the corresponding author.
32. Rhodes S, Richards DA, Ekers D, McMillan D, Byford S, Farrand PA, Gilbody G,
Hollon SD, Kuyken W, Martell C, O'Mahen HA, O'Neill E, Reed N, Taylor RS,
Watkins ER, Wright KA. Cost and outcome of behavioural activation versus
cognitive behaviour thrrapy for depression (COBRA): study protocol for a
randomised controlled trial. Trials. 2014;15:29.
33. Freire E, Elliott R, Westwell G. Person Centred and Experiential
Psychotherapy Scale (PCEPS): Development and reliability of an adherence/
competence measure for person-centred and experiential psychotherapies.
Counsel Psychother Res. 2014;14:220–6.
34. Blackburn I-M, James IA, Milne DL, Baker C, Standart S, Garland A, Reichelt
FK. The Revised Cognitive Therapy Scale (CTS-R): psychometric properties.
Behav Cogn Psychother. 2001;29:431–46.
35. Trepka C, Rees A, Shapiro DA, Hardy GE, Barkham M. Therapist competence
and outcome of cognitive therapy for depression. Cognitive Ther Res.
2004;28:143–57.
36. Sheehan D, Lecrubier Y, Sheehan H, Amorim P, Janavs J, Weiller E, Herguta
T, Baker R, Dunbar G. The Mini-International Neuropsychiatric Interview (M.I.
N.I.): the development and validation of a structured diagnostic psychiatric
interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22–33.
37. Leykin Y, DeRubeis RJ, Gallop R, Amsterdam JD, Shelton RC, Hollon SD. The
relation of patients’ treatment preferences to outcome in a randomized
clinical trial. Behav Ther. 2007;38:209–17.
38. Devilly GJ, Borkovec TD. Psychometric properties of the credibility/
expectancy questionnaire. J Behav Ther Exp Psy. 2000;31:73–86.
39. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a brief
depression severity measure. J Gen Intern Med. 2001;16:606–13.
40. American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Disorders. 5th edition. Arlington: American Psychiatric Publishing;
2013.
41. IAPT National Programme Team. The IAPT Data Handbook: Guidance on
recording and monitoring outcomes to support local evidence-based
practice: Version 2.0. London: IAPT National Programme Team; 2011.
42. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II.
San Antonio: Psychological Corporation; 1996.
43. Evans C, Connell J, Barkham M, Margison F, Mellor-Clark J, McGrath G, Audin
K. Towards a standardised brief outcome measure: psychometric properties
and utility of the CORE-OM. Br J Psychiatry. 2002;180:51–60.
44. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing
generalized anxiety disorder: The GAD-7. Arch Intern Med. 2006;22:1092–7.
45. Mundt JC, Marks IM, Shear MK, Greist JM. The Work and Social Adjustment Scale:
a simple measure of impairment in functioning. Br J Psychiatry. 2002;180:461–4.
46. The Euroqol Group. Euroqol—a new facility for the measurement of health-
related quality-of-life. Health Policy. 1990;16:199–208.
47. Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, Bonsel G,
Badia X. Development and preliminary testing of the new five-level version
of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.
48. Connor KM, Davidson JRT. Development of a new resilience scale: the
Connor-Davidson Resilience Scale (CD-RISC). Depress Anxiety. 2003;18:6–82.
49. Chisholm D, Knapp MRJ, Knudsen HC, Amaddeo F, Gaite L, van Wijngaarden B.
Client socio-demographic and service receipt inventory-European version:
Development of an instrument for international research. Br J Psychiatry.
2000;177:s28–33.
50. Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient
satisfaction: Development of a general scale. Eval Program Plann. 1979;2:197–207.
51. Cohen J. Statistical power analysis for the behavioural sciences. New York:
Lawrence Erlbaum; 1998.
52. Lipsey M. Design sensitivity: Statistical power for experimental research.
Newbury Park: Sage; 1990.
53. ICH harmonized tripartite guideline. Statistical principles for clinical trials
E9; Step 4: 1998.
54. Schumi J, Wittes JT. Through the looking glass: understanding non-
inferiority. Trials. 2011;12:106.
55. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJW. Reporting of
noninferiority and equivalence randomized trials: an extension of the
CONSORT statement. JAMA. 2006;295:1152–60.
56. Evans C, Margison F, Barkham M. The contribution of reliable and clinically
significant change methods to evidence-based mental health. Evid Based
Ment Health. 1998;1:70–2.
57. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining
meaningful change in psychotherapy research. J Consult Clin Psychol.
1991;59:12–9.
58. Richards DA, Suckling R. Improving access to psychological therapies: Phase
IV, prospective cohort study. Br J Clin Psychol. 2009;48:377–96.
59. National Institute for Health and Clinical Excellence (NICE). Guide to the
methods of technology appraisal. 2008.
60. Devlin N, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality
of life: An EQ-5D-5L value set for England. HEDS Discuss Pap Ser. 2016; 16(02).
61. The National Involvement Partnership. 4PI National Involvement Standards.
National Survivor User Network; 2013. Available at www.nsun.org.uk/assets/
downloadableFiles/4pi.-ni-standards-for-web.pdf
62. Ohlsen S, Ashley K, Saxon D, Barkham M. Putting PRaCTICED into practice:
bridging the gap between research and practice. Ther Today. 2015; 26;
December issue: 48–49.
63. Ashley K, Saxon D, Hardy GE, Barkham M. PRaCTICED trial: halfway there.
Ther Today. 2016; 27; November issue: 50–51.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Saxon et al. Trials  (2017) 18:93 Page 14 of 14
 1 
 
 
 
 
 
 
SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents* 
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page number 
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2b All items from the World Health Organization Trial Registration Data Set ____________ 
Protocol version 3 Date and version identifier _______6_____ 
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Roles and 
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5a Names, affiliations, and roles of protocol contributors __2,4,31-32____ 
5b Name and contact information for the trial sponsor _____31______ 
 5c Role of study sponsor and funders, if any, in study design; collection, management, analysis, and 
interpretation of data; writing of the report; and the decision to submit the report for publication, including 
whether they will have ultimate authority over any of these activities 
 
______31_____ 
 5d Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint 
adjudication committee, data management team, and other individuals or groups overseeing the trial, if 
applicable (see Item 21a for data monitoring committee) 
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Introduction 
   
Background and 
rationale 
6a Description of research question and justification for undertaking the trial, including summary of relevant 
studies (published and unpublished) examining benefits and harms for each intervention 
_____7-12_____ 
 6b Explanation for choice of comparators _____8-9______ 
Objectives 7 Specific objectives or hypotheses _____12_______ 
Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), 
allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) 
 
_____12______ 
Methods: Participants, interventions, and outcomes  
Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will 
be collected. Reference to where list of study sites can be obtained 
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Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and 
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11d Relevant concomitant care and interventions that are permitted or prohibited during the trial ______13_____ 
Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood 
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median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen 
efficacy and harm outcomes is strongly recommended 
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Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for 
participants. A schematic diagram is highly recommended (see Figure) 
___19-20______ 
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Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including 
clinical and statistical assumptions supporting any sample size calculations 
__22-23______ 
Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size _____23______ 
Methods: Assignment of interventions (for controlled trials) 
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Sequence 
generation 
16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any 
factors for stratification. To reduce predictability of a random sequence, details of any planned restriction 
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Allocation 
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mechanism 
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allocated intervention during the trial 
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Methods: Data collection, management, and analysis 
 
Data collection 
methods 
18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related 
processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of 
study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. 
Reference to where data collection forms can be found, if not in the protocol 
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 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be 
collected for participants who discontinue or deviate from intervention protocols 
______23_____ 
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Data management 19 Plans for data entry, coding, security, and storage, including any related processes to promote data quality 
(eg, double data entry; range checks for data values). Reference to where details of data management 
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Methods: Monitoring 
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whether it is independent from the sponsor and competing interests; and reference to where further details 
about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not 
needed 
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 21b Description of any interim analyses and stopping guidelines, including who will have access to these interim 
results and make the final decision to terminate the trial 
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Harms 22 Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse 
events and other unintended effects of trial interventions or trial conduct 
____29-30_____ 
Auditing 23 Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent 
from investigators and the sponsor 
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Ethics and dissemination  
Research ethics 
approval 
24 Plans for seeking research ethics committee/institutional review board (REC/IRB) approval ____12_______ 
Protocol 
amendments 
25 Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, 
analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, 
regulators) 
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Consent or assent 26a Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and 
how (see Item 32) 
___19-20______ 
 26b Additional consent provisions for collection and use of participant data and biological specimens in ancillary 
studies, if applicable 
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Confidentiality 27 How personal information about potential and enrolled participants will be collected, shared, and maintained 
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Declaration of 
interests 
28 Financial and other competing interests for principal investigators for the overall trial and each study site ____32_______ 
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participation 
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 31b Authorship eligibility guidelines and any intended use of professional writers _____________ 
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Appendices 
   
Informed consent 
materials 
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33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular 
analysis in the current trial and for future use in ancillary studies, if applicable 
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